merging evidence indicates that reactive oxygen species (ROS) are important molecules in the control of vascular reactivity. 1 Indeed, the superoxide anion (O 2 Ϫ ) increases vascular tone via the inactivation of endothelium-derived nitric oxide (NO). Recent studies, however, have revealed that the by-product of O 2 Ϫ metabolism, hydrogen peroxide (H 2 O 2 ), is a powerful endogenous vasodilator within the cerebral circulation. [2] [3] [4] [5] Thus, ROS may represent important signaling molecules for regulating local cerebral blood flow.
Numerous investigators have reported that NADPH oxidases are the primary generators of ROS within the vasculature. 6 -9 These enzymes are membrane-associated and generate O 2 Ϫ by transferring electrons to molecular oxygen via a flavin-containing "Nox" catalytic subunit. 10 In the systemic circulation, NADPH oxidase has been studied extensively, and it is now believed that excessive O 2 Ϫ generation by NADPH oxidase contributes to endothelial dysfunction associated with numerous cardiovascular diseases. 11 Although it has been recently established that NADPH oxidase is expressed and active in the cerebral circulation, [12] [13] [14] its function in this vascular bed is less clear. Application of the substrates for NADPH oxidase, NADPH or NADH, increases O 2 Ϫ production by cerebral arteries. [12] [13] [14] Interestingly, activation of NADPH oxidase using NADPH elicits profound cerebral vasodilatation in vitro 12 and in vivo, 13, 14 raising the possibility that in contrast with the systemic circulation, NADPH oxidase-derived ROS may normally play a functional role in vasodilator responses in the cerebral circulation. No study, however, has directly compared the activity and function of NADPH oxidase between systemic and cerebral circulations. Therefore, the aim of the present study was to test whether NADPH oxidase activity and function is normally greater in rat cerebral versus systemic arteries.
O 2 ؊ Production by NADPH Oxidase in Intact Cerebral and Systemic Arteries
Basilar, middle cerebral, common carotid, mesenteric (2nd order branch of the superior mesenteric artery), and renal arteries and thoracic aorta were excised and cut into 5 mm-long ring segments. O 2 Ϫ production was measured by 5 mol/L lucigenin-enhanced chemiluminescence in the absence and presence of NADPH (100 mol/L) as previously described. 15 In some experiments, arteries were treated with the Cu 2ϩ -chelating agent diethyldithiocarbamate (DETCA; 3 mmol/L) for 30 minutes before start of assay (to inhibit endogenous Cu 2ϩ /Zn 2ϩ superoxide dismutase [SOD] activity), in the presence and absence of angiotensin II (0.1 mol/L) and/or the NADPH oxidase inhibitors diphenyleneiodonium (DPI; 5 mol/L), apocynin (300 mol/L), and gp91ds-tat (RKKRRQRRRCSTRIRRQL-CONH2; 1 mol/L). In experiments using apocynin and gp91ds-tat, arteries were incubated with drugs for 1 hour before addition of NADPH and DETCA. Additionally, experiments in NADPH-treated basilar arteries were performed in the presence of the NO synthase (NOS) inhibitor N-nitro-L-arginine methyl ester (L-NAME; 100 mol/L). Background counts were subtracted and O 2 Ϫ production normalized for dry tissue weight.
O 2 ؊ Production by NADPH Oxidase in Cerebral and Systemic Artery Homogenates
Basilar, common carotid, and mesenteric (2nd order branch of the superior mesenteric artery) arteries and thoracic aorta were excised and cut into 5 mm-ring segments. Arteries were homogenized in either 70 L (basilar and mesenteric) or 90 L (carotid and aorta) of lysis buffer (composition in mmol/L: sucrose 250, HEPES 10) with protease inhibitors (Roche Complete Mini, #1836153) using 0.2 mL glass homogenizers. O 2 Ϫ production was measured by 5 mol/L lucigenin-enhanced chemiluminescence in the presence of NADPH (100 mol/L) and DETCA (3 mmol/L). Background counts were subtracted and values were normalized to protein content (as measured using the Bradford protein assay; BioRad).
Localization and Semiquantification of O 2

؊ by Dihydroethidium
Dihydroethidium (DHE; 2 mol/L) was used to localize and measure O 2 Ϫ production in frozen sections (16-m) of basilar and common carotid arteries and thoracic aorta as previously described. 15, 16 In the presence of O 2 Ϫ , DHE is oxidized to ethidium and oxyethidium, which intercalate between DNA strands, producing a nuclear staining pattern. Arterial sections were treated with NADPH (100 mol/L) for 30 minutes before treatment with DHE. Some sections were treated with polyethylene glycol-SOD (PEG-SOD, 250 U/mL) or native Cu 2ϩ /Zn 2ϩ -SOD (250 U/mL) for 30 minutes before incubation with DHE. Fluorescent images were acquired as 8-bit (256 intensity levels) and were analyzed with Image-Pro Plus software (version 5.0.1.11, Media Cypernetics Inc). For each arterial section, pixels in the upper 50% intensity level were counted, background fluorescence was subtracted, and data were presented as total fluorescent units per mm 2 of cross sectional artery wall area.
Expression of Nox4
Expression of Nox4 in basilar, common carotid, and mesenteric arteries (2nd order branch of the superior mesenteric artery) and thoracic aorta was measured by Western blotting. Anti-Nox4 rabbit polyclonal antibodies were raised against the Nox4 peptide (aa 84 to 101; RGSQKVPSRRTRRLLDKS). We have previously demonstrated that preincubation of Nox4 antibody sera with Nox4 peptide (10 g/mL) results in undetectable immuoreactive bands, implying specificity of the Nox4 antibody. 17 Arteries were homogenized in ice-cold lysis buffer (composition in mmol/L: sucrose 250; HEPES 10) with protease inhibitors (Roche Complete Mini, #1836153) using 0.2 mL glass homogenizers. Homogenates were cleared by centrifugation (10 000 relative centrifugal force; 5 minutes) and protein concentration was determined using the Bradford protein assay (BioRad 
In Vitro Protocol
Rings were again contracted submaximally (50% to 60% of contraction to KPSS) with either serotonin (basilar, aorta, and mesenteric) or U46619 (carotid). Once contractions were stable, the effects of the following agonists on vascular tone were investigated: NADPH (10 and 100 mol/L), sodium nitroprusside (SNP; 0.01 to 1 mol/L), and H 2 O 2 (10 to 1000 mol/L). Responses were examined in the presence and absence of apocynin (300 mol/L) or the H 2 O 2 scavenger catalase (1000 U/mL). In some experiments, arteries were contracted submaximally (20% of contraction to KPSS) with KCl (20 mmol/L). Once contractions were stable, the effect of angiotensin II (100 nmol/L) on vascular tone in the presence and absence of catalase (1000 U/mL) or apocynin (300 mol/L) was investigated. Arteries were treated with apocynin for 90 minutes before experiments commenced.
Drugs
H 2 O 2 was purchased from Merck, DHE from Molecular Probes, angiotensin II from Auspep, apocynin from Fluka, and gp91ds-tat from SynPep Corporation. All other drugs were purchased from Sigma. DPI, DHE, and apocynin were prepared at 10 mmol/L in dimethyl sulfoxide (DMSO) and diluted in Krebs-HEPES solution such that the final concentration of DMSO was Ͻ0.05% to 0.001%. All other drugs were dissolved and diluted in either Krebs-HEPES (lucigenin/DHE experiments) or Krebs-bicarbonate (myograph/organ bath experiments) solution.
Data Analysis
All results are expressed as meanϮSEM. Statistical comparisons were performed using either 1-way ANOVA with Bonferroni multiple comparisons post hoc-test or using Student paired or unpaired t test, as appropriate. PϽ0.05 was considered statistically significant.
Results
O 2 ؊ Production by NADPH Oxidase in Cerebral and Systemic Arteries
Basal O 2 Ϫ production (counts measured in the absence of NADPH) by intact basilar and middle cerebral arteries was higher (up to 120-fold) than levels generated by the aorta and carotid, mesenteric, and renal arteries (PϽ0.05, Figure 1A ). Similarly, in the presence of NADPH, O 2 Ϫ production by basilar and middle cerebral arteries was markedly higher (10-to 90-fold) than levels generated by aorta and carotid, mesenteric, and renal arteries (PϽ0.001, Figure 1B ). When arteries were treated with the Cu
Ϫ levels in all vessels were augmented; however, O 2 Ϫ levels in basilar and middle cerebral arteries remained profoundly greater than levels in systemic arteries (PϽ0.01, Figure 1B ). In arterial homogenates, NADPH-stimulated O 2 Ϫ production (in the presence of DE-TCA) was also substantially higher in basilar arteries than in the aorta and carotid and mesenteric arteries (PϽ0.01, Figure  1C ). The NADPH oxidase inhibitor DPI virtually abolished NADPH-stimulated O 2 Ϫ production in all intact arteries (PϽ0.01, Figure 1B ). Moreover, in basilar arteries, the selective NADPH oxidase inhibitors apocynin and gp91ds-tat inhibited NADPH-stimulated O 2 Ϫ production (PϽ0.05, Figure 1D ). The NOS inhibitor L-NAME (100 mol/L) had no significant effect on NADPH-stimulated O 2 Ϫ production by basilar arteries (control, 5.9Ϯ0.6; L-NAME 6.6Ϯ0.6ϫ10 3 counts/mg of dry tissue; nϭ6, PϾ0.05, 1-way ANOVA), suggesting that NADPH oxidase (and not NOS) was the primary source of vascular O 2 Ϫ . In the presence of NADPH (100 mol/L) and DETCA (3 mmol/L), angiotensin II (30
Ϫ production in all arteries. Angiotensin II-induced increases in O 2 Ϫ production were 30-to 120-fold greater in basilar arteries than in similarly-treated aorta and carotid and mesenteric arteries (PϽ0.01, Figure 2 ).
Localization of O 2
؊ Production by NADPH Oxidase
Ϫ production by NADPH oxidase was localized and measured in arterial sections of basilar and carotid arteries and aorta using DHE. In the presence of NADPH, ethidium/ oxyethidium fluorescence was observed throughout the vascular wall of all arteries, but was substantially higher in basilar arteries than in carotid arteries or aorta (PϽ0.001, Figure 3A through 3C). In basilar arteries, fluorescence intensity was uniform throughout all cell types, whereas in carotid arteries and aorta, fluorescence was more intense in endothelial and adventitial cells than in vascular smooth muscle cells ( Figure 3A through 3C) . Treatment of sections with PEG-SOD inhibited fluorescence in all arteries (PϽ0.01, Figure 3D through 
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shown), indicating that the DHE fluorescence reflected intracellular O 2 Ϫ .
Nox4 Expression
Expression of Nox4 protein was 10-fold greater in basilar arteries than in the aorta (Figure 4 ; PϽ0.05). Expression of Nox4 protein in common carotid and mesenteric arteries was similar to that found in aorta (data not shown).
Effect of NADPH on Vascular Tone
ACh (10 mol/L) elicited similar relaxation responses in all arteries (basilar, 82Ϯ4%; aorta, 82Ϯ3%; carotid, 92Ϯ2%; mesenteric, 87Ϯ3%), indicating a functional endothelium. NADPH (10 to 100 mol/L) elicited concentrationdependent relaxations of all arteries ( Figure 5A ). NADPHinduced relaxations of basilar arteries, however, were significantly greater than responses of carotid arteries and aorta (PϽ0.01, 1-way ANOVA). This enhanced relaxation was selective for NADPH, as relaxations to SNP were similar in all 4 arteries ( Figure 5B ). Furthermore, apocynin (300 mol/L) virtually abolished NADPH-induced relaxation in the basilar artery but had no effect on ACh-induced (0.1 mol/L) relaxation, suggesting that NADPH oxidase activity was responsible for mediating these effects (PϽ0.05, paired t test; Figure 5C and 5D; data shown only for 100 mol/L NADPH).
Vascular Responsiveness to Endogenous and Exogenous H 2 O 2
In basilar, carotid, and mesenteric arteries, relaxations to NADPH (10 to 100 mol/L) were either abolished or inhibited by catalase (1000 U/mL; PϽ0.01; Figure 6A ; data shown only for 100 mol/L NADPH). In contrast, NADPH- induced relaxations of the aorta were potentiated by catalase (PϽ0.01). Interestingly, in the presence of catalase, NADPH elicited small, transient contractions of basilar and carotid arteries (Ϸ20% of pre-contracted tone, Figure 6A ). Catalase had no effect on relaxations to SNP (1 mol/L, Figure 6B ), however. These experiments suggest that relaxations to NADPH are mediated by endogenous H 2 O 2 , presumably derived from NADPH oxidase, in all arteries except the aorta.
We next compared the sensitivity of cerebral and systemic arteries to exogenous H 2 O 2 . In all arteries, exogenous H 2 O 2 (10 to 1000 mol/L) induced a biphasic response: A small transient contraction followed by a large, sustained relaxation. There were no differences between arteries with respect to H 2 O 2 -induced contractions (data not shown); however, relaxations to H 2 O 2 (100 to 1000 mol/L) were greater in basilar and mesenteric arteries when compared with aorta and carotid arteries (PϽ0.01, Figure 7A ). In all arteries, catalase abolished relaxations to H 2 O 2 (PϽ0.01, Figure 7B ).
Effect of Angiotensin II on Vascular Tone
Angiotensin II (100 nmol/L) elicited contractions of all arteries ( Figure 8A ), but those contractions were smaller in the basilar artery than in systemic arteries (PϽ0.05, 1-way ANOVA). Treatment with catalase resulted in a 3-fold increase in angiotensin II-induced contractions of the basilar artery, but not the systemic arteries (PϽ0.01, 1-way ANOVA; Figure 8A ). Similarly, in the presence of apocynin, there was a 3-fold increase in angiotensin II-induced contractions of the basilar artery (PϽ0.05, paired t test; Figure 8B ).
Discussion
The findings of this study reveal striking differences between intracranial cerebral arteries and a range of systemic arteries with respect to the activity, function, and expression of the ROS-generating enzyme NADPH oxidase. Specifically, using 2 separate techniques, we found that basal and stimulated 
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O 2 Ϫ generation from NADPH oxidase is 1 to 2 orders of magnitude higher in cerebral arteries than in systemic arteries. The higher level of NADPH oxidase-derived O 2 Ϫ in the basilar artery was associated with a 10-fold higher expression of the catalytic subunit protein Nox4. Activation of NADPH oxidase in vitro elicited relaxation of all arteries, but this response was greatest in cerebral arteries. Thus, we report for the first time that the activity, expression, and function of NADPH oxidase is profoundly greater in cerebral than systemic arteries. Like NADPH, angiotensin II was found to be a much stronger stimulus for NADPH oxidase activity in the basilar artery, where its contractile efficacy appears to be modulated by endogenous H 2 O 2 . These findings support the concept that NADPH oxidase-derived ROS may play a physiological role in regulating cerebral blood flow.
NADPH Oxidase Activity and Cerebral Arteries
NADPH oxidase is normally expressed and functional in both the cerebral and systemic vasculature. 6 -8,12-14 When increased to supranormal levels by cardiovascular risk factors, NADPH oxidase activity is thought to be linked to endothelial dysfunction associated with various cardiovascular diseases. 11 However, it is not known what role, if any, is played by NADPH oxidase-derived ROS in modulating vascular function in the systemic circulation under normal physiological conditions. In contrast, findings from recent studies have raised the possibility that NADPH oxidase-derived ROS may serve as an important physiological vasodilator mechanism in the cerebral circulation. 13, 14 Using the chemiluminescent probe lucigenin, we found that either angiotensin II or the substrate for NADPH oxidase, NADPH, increased O 2 Ϫ production in intact cerebral and systemic arteries, and this effect was inhibited by the NADPH oxidase inhibitors DPI, apocynin, and gp91ds-tat. Moreover, inhibition of NOS had no effect on O 2 Ϫ production in basilar arteries, providing strong evidence that NADPH oxidase was the primary source of O 2 Ϫ detected by this assay. A striking observation in these experiments was that O 2 Ϫ production by NADPH oxidase was profoundly greater in intracranial cerebral arteries (ie, basilar and middle cerebral) versus systemic arteries (ie, aorta, carotid, renal, and mesenteric). Furthermore, a considerably higher NADPH oxidase activity was also found in arterial homogenates of cerebral versus non-cerebral vessels, confirming that this phenomenon is not dependent on the presence of whole arterial tissue or even intact cells, and is consistent with a regional difference in enzyme subunit expression levels (see below). Because detected levels in cerebral arteries remained up to 75-fold higher even when Cu 2ϩ /Zn 2ϩ -SOD was inhibited by DETCA, it seems likely that this regional difference is, in large part, due to differing levels of NADPH oxidase activity and not simply varying degrees of O 2 Ϫ inactivation. In addition to the quantitative chemiluminescence data, we localized and measured O 2 Ϫ production in NADPH-treated basilar arteries, aorta, and carotid arteries using the oxidative fluorescent dye dihydroethidium. Ethidium/oxyethidium fluorescence was visible in endothelial, vascular smooth muscle, and adventitial cells of basilar and carotid arteries and the aorta, indicating that NADPH oxidase is expressed and active throughout the vasculature of all these arteries. Although the range and resolution of O 2 Ϫ detection may differ between the 2 methodologies, making it difficult to strictly compare quantitative findings from each approach, using both assays we found markedly greater levels of O 2 Ϫ production in basilar arteries versus systemic and/or non-intracranial arteries. Thus, together these results provide strong evidence that NADPH oxidase activity is substantially greater in the cerebral circulation versus systemic vasculature under physiological conditions.
Nox4 Expression
We have previously reported that Nox4 mRNA expression is abundant in the rat basilar artery and is augmented during chronic hypertension. 13 We now report that Nox4 protein expression is markedly higher in the basilar artery than in systemic arteries. Although the associated higher expression of Nox4 protein in cerebral versus systemic arteries seems likely to contribute to the higher relative production of ROS by cerebrovascular NADPH oxidase, we cannot exclude the possibility that other Nox subunits, such as Nox2 and Nox1, might also contribute substantially to this regional difference. Of relevance here is our finding that the inhibitors of the association of cytosolic and membrane-associated NADPH oxidase components, apocynin and gp91ds-tat, both inhibited the NADPH-induced superoxide production by Ϸ50% in the basilar artery. Furthermore, a recent study has reported that when expressed in cultured cells, Nox4, unlike Nox2, does not appear to require cytosolic components to function. 18 Thus, it is conceivable that other Nox proteins, including Nox2 and Nox1, may also contribute to the molecular basis of higher NADPH oxidase activity in cerebral arteries.
NADPH Oxidase Function and Cerebral Arteries
We next tested for any regional differences in the regulation of vascular tone associated with these differing levels of NADPH oxidase activity. Recent studies in rats, rabbits, and mice have shown that NADPH causes cerebral vasodilatation in vivo and in vitro. [12] [13] [14] We confirmed here that application of NADPH to isolated basilar arteries elicits powerful cerebral vascular relaxation. Because in systemic arteries activation of NADPH oxidase and generation of O 2 Ϫ is generally thought to increase vascular tone via the inactivation of endothelium-derived NO, 19, 20 it was somewhat surprising to find that NADPH consistently elicited relaxations of all 3 systemic arteries. Most notable, however, was the finding that cerebral (basilar) arteries were more responsive in terms of relaxation to NADPH than systemic arteries. This enhanced vasodilatation was relatively specific for NADPH, as relaxations to the endothelium-dependent vasodilator ACh and the endothelium-independent vasodilator SNP were similar in all artery types. Of importance, apocynin virtually abolished NADPH-induced relaxation of the basilar artery, providing strong evidence that the relaxant effect of NADPH is NADPH oxidase-dependent. Interestingly, apocynin appears to inhibit NADPH-induced cerebral relaxation more effectively than it inhibits NADPH-induced O 2 Ϫ production. This may reflect differences in the accessiblity of apocynin to NADPH oxidase in the different experimental procedures, or may perhaps suggest that only apocynin-sensitive Nox homologues contribute to the vasodilatation.
The identity of the NADPH oxidase-derived ROS responsible for mediating cerebral vasodilatation to NADPH is not well defined. We previously reported that NADPH-induced dilatation of rat basilar arteries in vivo were inhibited by catalase and DETCA, suggesting that H 2 O 2 (or a downstream ROS) generated from the dismutation of O 2 Ϫ by Cu 2ϩ /Zn 2ϩ -SOD was responsible for the vasodilatation. 13 In contrast, a recent study in mice found that O 2 Ϫ and not H 2 O 2 was partially responsible for cerebral vasodilatation to NADPH. 14 In the present study, we found that catalase abolished NADPH-induced relaxation of cerebral arteries without affecting responses to SNP, indicating that the effect of NADPH was mediated by endogenous H 2 O 2 (or a downstream ROS thereof) and that the effects of catalase were independent of contractile agents used in arterial preparations. We confirmed here previous reports that H 2 O 2 is a powerful endogenous cerebral vasodilator. 3, 4 Thus, cerebral arteries appear to be not only very sensitive to the relaxant effect of H 2 O 2, but also likely to generate much higher amounts of H 2 O 2 in response to stimuli of NADPH oxidase by virtue of a much higher activity of this enzyme relative to systemic arteries. The greater cerebral vasodilator response to NADPH is therefore likely to be a consequence of both higher ROS generation by NADPH oxidase and greater sensitivity to H 2 O 2 of cerebral arteries.
The present findings using extracellular NADPH as an activator of NADPH oxidase do, however, raise an important question: How does extracellular NADPH increase NADPH oxidase activity when the substrate binding domain is believed to be intracellular? 21 One potential explanation is that application of NADPH to the extracellular milieu results in elevated intracellular levels of the pyridine nucleotide. NADPH is a relatively large, highly charged molecule, however, and is therefore unlikely to cross the plasma membrane by simple diffusion. Hence, to influence the intracellular concentration of NADPH, extracellular NADPH would either have to be actively transported across the plasma membrane or pass through a channel. Alternatively, NADPH could conceivably act as a reducing equivalent for regeneration of intracellular NADPH from NADP ϩ by donating electrons either to a plasma membrane spanning electron transport protein or to a membrane permeable electron acceptor (ie, analogous to the mitochondrial citrate/ pyruvate shunt). To date, there is no information on the existence of such mechanisms in vascular cells, or indeed in any other mammalian cell types, nor is there any published evidence on whether extracellular NADPH influences the intracellular concentration of the pyridine nucleotide. Nevertheless, the observations that NADPH-induced ROS production and cerebral vasodilatation in vitro and in vivo can be attenuated by specific NADPH oxidase inhibitors and gene knockdown approaches (present study and others 9, [12] [13] [14] 22 ) suggest that NADPH, either directly or indirectly, triggers NADPH oxidase activation.
Indeed, we found here that angiotensin II potentiated vascular O 2 Ϫ production, and this effect was markedly greater (100-fold) in basilar arteries compared with aorta. Interestingly, this is analogous to our previous finding in spontaneously hypertensive rats, where O 2 Ϫ production from NADPH oxidase was selectively enhanced in basilar arteries. 13 Thus, vasodilator ROS production stimulated by angiotensin II in cerebral arteries would be expected to offset and hence protect against angiotensin II-induced cerebral vasospasm. Consistent with this hypothesis is our present finding that catalase and apocynin can substantially and selectively augment cerebral vasoconstriction by angiotensin II. Mechanical forces, including cyclic stretch and laminar and oscillatory shear stress, have also been shown to increase NADPH oxidase activity in endothelial cells, 23, 24 and we have recently reported that NADPH oxidase-derived ROS partly mediate flow-dependent responses of the basilar artery in vivo. 25 Thus, it is possible that NADPH oxidase-derived ROS serve as important secondary messengers and/or paracrine signaling factors in endothelial cells of the cerebral circulation, increasing blood flow in response to hormonal and physical stimuli. It is therefore noteworthy that the present results support the concept that the phenomenon of high NADPH oxidase activity in cerebral arteries is physiologically relevant and is not limited to studies using exogenous NADPH as a stimulus.
In summary, this study has demonstrated that under normal conditions, NADPH oxidase activity is profoundly greater in cerebral versus systemic arteries. Activation of NADPH oxidase in cerebral arteries can cause powerful vasodilatation and offset angiotensin II-induced vasoconstriction via H 2 O 2 derived from the dismutation of NADPH oxidase-derived O 2 Ϫ . These findings are associated with markedly higher expression of the Nox4 catalytic subunit of NADPH oxidase in cerebral than in systemic arteries. Our findings raise the prospect that NADPH oxidasederived ROS may play an important role in the control of cerebral vascular tone. If so, caution may need to be taken in the future use of therapies to inhibit the effect of ROS in systemic vascular disease so as not to inadvertently compromise cerebral blood flow.
